Sorrento Therapeutics Inc (SRNE): Sorrento are asking for Breakthrough Des...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	57
Posts	5700
Boards Moderated	0
Alias Born	12/13/2004

dia76ca

Re: None

Wednesday, 02/02/2022 9:18:24 PM

Wednesday, February 02, 2022 9:18:24 PM

Sorrento are asking for Breakthrough Designation for non-opioid SEMDEXA for sciatica. FDA must respond to this request in 60 days after application. If granted, sales could begin in US mid-year 2022! Sales force is already in place. US sales are estimated between $5-10 billion annually, and with label expansion, additional 50-200%. This is a game changer!

"The refusal of the real is the number one dogma of our time" Rene Girard

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent SRNE News

Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:31:06 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:15:31 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 01:51:06 AM
Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 09:25:07 PM
Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/07/2023 08:15:35 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 10:01:54 AM
Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 10:26:26 AM